Share Name Share Symbol Market Type Share ISIN Share Description
Amryt Pharma Plc LSE:AMYT London Ordinary Share GB00BKLTQ412 ORD 6P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 122.50 120.00 125.00 122.50 122.50 122.50 16,738 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 13.0 -23.1 -8.4 - 266

Amryt Pharma Share Discussion Threads

Showing 5251 to 5274 of 5275 messages
Chat Pages: 211  210  209  208  207  206  205  204  203  202  201  200  Older
DateSubjectAuthorDiscuss
13/11/2019
16:01
O/T. Big drop in the ECO share price today following the RNS. Glad I no longer dabble in speculative AIM O&G's. I'm just gambling on an AIM listed speculative biotech, AMYT, instead!
papillon
11/11/2019
21:56
Two massive trades timed at just before 1pm, but only reported after the market closed. Both sells, but the share price responded by going up! I wonder if the trades have been worked over a number of days and have been depressing the share price and that now they have gone the share price will start to rise? These are the two trades: 400,000 @ 115.625p and timed @ 12:55:07. Proceeds £462,500,000 474,135 @ 115.50p and timed @ 12:54:15. Proceeds £547,630,000
papillon
10/11/2019
18:03
hTTps://www.thetimes.co.uk/article/agenda-mystery-rises-as-bank-of-china-goes-for-irish-broker-goodbody-cttf2090r Wiley in the right with Amryt Perhaps you should have paid attention in biology class. Joe Wiley, chief executive, and Rory Nealon, chief financial officer, were last week granted options over 10.2m shares in Amryt Pharma, an Irish drug developer. The bumper share awards have an exercise price of £1.215p each. Amryt is an orphan drug specialist, finding treatments for rare diseases. The company recently acquired Aegerion, a Canadian peer and has a drug in development to treat the skin disease epidermolysis bullosa. There are no sure things in pharma, yet Wiley has a top reputation and a nose for a deal. The rewards here could be truly massive. Wiley by name, wily by nature. brian.carey@sunday-times.ie
papillon
10/11/2019
17:19
Yep Sunday Times
alphabravo321
10/11/2019
13:07
alphabravo321, you posted the following on the lse bb today. Does ST refer to the Sunday Times? tia alphabravo321 Posts: 33 Price: 121.00 No Opinion ST Today 05:30 Wiley in the right with Amryt Perhaps you should have paid attention in biology class. Joe Wiley, chief executive, and Rory Nealon, chief financial officer, were last week granted options over 10.2m shares in Amryt Pharma, an Irish drug developer. The bumper share awards have an exercise price of £1.215p each. Amryt is an orphan drug specialist, finding treatments for rare diseases. The company recently acquired Aegerion, a Canadian peer and has a drug in development to treat the skin disease epidermolysis bullosa. There are no sure things in pharma, yet Wiley has a top reputation and a nose for a deal. The rewards here could be truly massive. Wiley by name, wily by nature.
papillon
06/11/2019
13:07
LOL, purple11. Don't forget to wake me up! "So wake me up when it's all over When I'm wiser and I'm older"
papillon
06/11/2019
11:31
nite pappy
purple11
06/11/2019
11:30
Back to sleep, until the next RNS.
papillon
05/11/2019
22:37
https://www.irishtimes.com/business/health-pharma/dublin-pharma-company-amryt-grows-sales-almost-20-1.4072998?mode=amp
tiananmen
05/11/2019
19:56
"It looks undervalued at less than 2 x full year sales. Cash helps but will get spent." Don't forget AMYT has debt, waterloo. The amount of debt must also be acknowledged in any attempt at valuing AMYT. Don't forget we've already had a broker note, waterloo. Stiffel's valuation dated 1st October. That was first posted by Bronxville on the lse bb and copied by me onto this bb last week (post 5087). Stiffel reckon … … … "that revenue-generative orphan drug companies trade at 8.8-times historic earnings." Seems rather fanciful to me, but even 4 x historic earnings valuation gives a 240p AMYT share price
papillon
05/11/2019
19:24
£zillions........! Sorry, don’t have the expertise - guess that makes me a gambler and not an investor! At least I’m a very patient gambler.... Fingers very firmly crossed!
bazworth
05/11/2019
18:55
Well at least they are not free options but have a strike price of £1.21. Makes them as keen as shareholders to see the share price climb. Would love to see a broker note. Any around? It looks undervalued at less than 2 x full year sales. Cash helps but will get spent. Hopefully the combined entity has a reasonable cost base. Any thoughts on appropriate valuation based on revenue now it's more visible?
waterloo01
05/11/2019
18:48
Hope it’s positive!
bazworth
05/11/2019
18:39
Timing of the options grant is telling in my opinion
alphabravo321
05/11/2019
18:23
Big options grant for the lads
alphabravo321
05/11/2019
17:17
Big buy just after 4pm. 106,352 @ 122.50p. Cost £130.28k.
papillon
05/11/2019
14:23
ADVFN have blocked the link I posted in my previous post because of the word proactive in the link. So here is the YouTube link to the same video and Rory Nealon interview today. https://www.youtube.com/watch?v=dSxt_45OOPo&t=33s In the interview, alphabravo, Rory Nealon just states that a Nasdaq listing is under consideration. No firm date. No confirmation it will happen within the 90 day period since 24th September.
papillon
05/11/2019
14:05
I am sticking with the commitment in the admission doc of seeking a Nasdaq listing within 90 days of deal closure which was Sep 24th.
alphabravo321
05/11/2019
13:41
jupiternmars Posts: 1,286 Price: 121.50 No Opinion Rory Nealon - Proactive Today 13:16 [...] >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> It's well worth watching the video and listening to Rory Nealon being interviewed. The Nasdaq listing is commented on at the end of the interview by Nealon when questioned about it. It doesn't appear to be imminent.
papillon
05/11/2019
12:39
Good sales figures, waterloo, but disappointed with the lack of news on the Nasdaq listing and a lower cash balance than I expected (US$61.2m = £47.44m at 31st October). Combined sales revenue of US$113.1m for the first 9 months of 2019 implies combined sales revenue of US$150.8m for the whole of 2019. That's inline with market expectations.
papillon
05/11/2019
12:14
Yes noticeably absent. No idea why.
waterloo01
05/11/2019
12:10
No mention of the Nasdaq listing in today's RNS. Cash balance of US$61.2m (£47.44m) @ 31st October.
papillon
05/11/2019
11:12
surprised at the lack of trades here. Any broker notes or updates?
gucci
05/11/2019
07:35
Results look excellent. Continued growth.
waterloo01
Chat Pages: 211  210  209  208  207  206  205  204  203  202  201  200  Older
Your Recent History
LSE
AMYT
Amryt Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191113 19:46:53